$ZBH

Bernstein Adjusts Price Target on Zimmer Biomet to $93 From $91

Bernstein raised its price target on Zimmer Biomet to $93 from $91, according to the report. The article also notes a separate Jefferies price target change to $105 from $95. Investors may use these analyst updates as inputs for valuation and expectations for the stock.

Original reporting
Published Aug 6, 2026, 5:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 3:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ZBH
Neutral
low confidence
Mentioned
$ZBH
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ZBHNeutralLow
01

Why it matters

This is primarily a valuation/sentiment update rather than a new operational or regulatory development.

02

Market read

For ZBH, the actionable signal is the updated analyst valuation target, which may influence short-term sentiment but lacks new fundamental disclosures in the text.

03

What to watch

Traders may care more about the accompanying analyst rationale, changes in EPS estimates, or whether other firms moved targets the same day, none of which are included here.

Relevance 4/10Novelty 3/10Timing: market closed, analyst target update reported after the close

Background

The article is a sell-side note summary reporting Bernstein’s updated price target for Zimmer Biomet.

Company-level read

Ticker impact

$ZBHNeutralLow confidence
Context

Bernstein cut/adjusted its Zimmer Biomet price target to $93 from $91, signaling a fresh valuation view for ZBH shares.

Expected impact

Likely modest, short-lived reaction unless other analysts or company-specific news corroborate the change.

Evidence & confidence

The text only states the target adjustment and does not include earnings, guidance, or new company-specific operating data.

Market effects

Minor read-through for medical device valuation sentiment, but no sector-wide catalyst is provided.

No specific regional linkage beyond general US-listed analyst coverage.

Limited, as the update is a single-name sell-side target change without broader global developments.

Counterpoint

Price-target changes often lag or reflect existing consensus; without new fundamentals, the market may largely ignore it.

Key entities

  • Zimmer Biomet

    US-listed medical device company referenced as the subject of Bernstein’s price-target adjustment.

  • Bernstein

    Sell-side firm adjusting its Zimmer Biomet price target to $93 from $91.

Related articles

$ZBHMed

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

$ZBHMedAI 8/10

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

$ZBHHighAI 9/10

ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.